Ultragenyx Pharmaceutical, Kyowa Kirin bag Crysvita FDA approval for TIO
Crysvita FDA approval for TIO : Ultragenyx Pharmaceutical and Kyowa Kirin have secured approval for their recombinant fully human monoclonal IgG1 antibody Crysvita (burosumab) from the US Food and Drug Administration (FDA) for the treatment of tumor-induced osteomalacia (TIO). The FDA approval of Crysvita is for the treatment of fibroblast growth factor 23 (FGF23)-related hypophosphatemia […]